A
AiVita Biomedical
Medicine company develops commercial and clinical stage programs utilizing curative and regenerative medicines
About AiVita Biomedical
AIVITA Biomedical is a cutting-edge immuno-oncology company founded in 2016. The company specializes in creating personalized vaccines aimed at targeting the root cause of all cancers, known as tumor-initiating cells. These cells are the seeds from which cancer grows. AIVITA leverages its deep expertise in stem cell growth and precise differentiation to develop safe, efficient, and cost-effective manufacturing processes for cancer therapies and other medical fields.
AIVITA Biomedical primarily serves patients battling various forms of cancer. The company operates in the biotechnology and healthcare markets, focusing on innovative cancer treatments. Their business model revolves around the development and commercialization of personalized cancer vaccines. These vaccines are tailored to each patient's unique tumor profile, aiming to provide a more effective and targeted treatment option.
The company generates revenue through multiple streams. Firstly, it raises funds through financing rounds, such as the recent $12.5 million Series B2 round. Secondly, it sells innovative skincare products that utilize growth factors from skin stem cells. These products are clinically proven to support skin maintenance and renewal. Importantly, all proceeds from skincare sales are directed towards funding ovarian cancer treatments, showcasing the company's commitment to both innovation and social responsibility.
AIVITA Biomedical has also made significant strides in COVID-19 research, with its CEO, Hans Keirstead, being recognized for his contributions. The company is actively involved in clinical trials, including a Phase 2 trial for glioblastoma, a type of brain cancer, demonstrating its ongoing commitment to advancing cancer treatment.
In summary, AIVITA Biomedical is a pioneering company in the field of immuno-oncology, dedicated to developing personalized cancer vaccines and innovative skincare products, with a strong focus on research and social impact.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 21
- Open positions
- 2
- Dealroom signal
- 40.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Skin Care, Wellness and Beauty, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2022 | $85M | $340M | Undisclosed | ↗ |
| EARLY VCOther financing | Aug 2022 | $6M | $24M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for AiVita Biomedical is 3K monthly website visits, up 215.8% over the last three months. AiVita Biomedical's team grew 5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AiVita Biomedical in the Irvine ecosystem
The AiVita Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series A1 investor entered at this stage
California Technology Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AiVita Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AiVita Biomedical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









